Targeting LSD1 in Prostate Cancer
靶向 LSD1 治疗前列腺癌
基本信息
- 批准号:8933574
- 负责人:
- 金额:$ 21.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-09-19 至 2018-08-31
- 项目状态:已结题
- 来源:
- 关键词:AndrogensApoptosisAutomobile DrivingBiologicalBiopsyBromodomainCastrationCategoriesCell Cycle RegulationCell DeathCell LineCell ProliferationCell SurvivalCellsChromatinClinicalDataDependencyDevelopmentDrug KineticsEnrollmentEnzymesEvaluationGene TargetingGrowthImplantIn VitroInstructionLigandsMalignant neoplasm of prostateMeasuresMediatingModelingMusNeurosecretory SystemsOutcomePacific NorthwestPathway interactionsPatientsPhasePhase I Clinical TrialsPropertyProteinsRNA InterferenceResistanceRoleSafetyShapesSignal TransductionSpecificityTranslatingXenograft ModelXenograft procedureabirateroneaddictionbasec-Myc Staining Methodc-myc Genesclinically relevantimprovedin vivoinhibitor/antagonistinnovationinsightmennoveloverexpressionphase 1 studypre-clinicalpreclinical studypreventresponsetherapeutic targettumortumor growth
项目摘要
PROJECT SUMMARY (See instructions):
Despite the introduction of new AR pathway inhibitors such as abiraterone and MDV3100, clinical responses are transitory and many patients do not respond, demonstrating the importance of ligand and AR-independent mechanisms of PCa progression. This proposal evaluates the novel hypothesis that the chromatin modifying enzyme LSD1 mediates survival of ligand and AR-independent CRPC (extending its previously identified function as a driver of ligand-mediated AR activity). Specifically, we find that i. LSD1 overexpression is ubiquitous in metastatic CRPCs, including AR+ and AR- tumors; ii. the predominant category of ligand-independent LSD1 target genes involves control of the cell cycle and proliferation; and iii. LSD1 acts in an AR-axis independent manner by promoting cMyc driven tumor growth. Our data re-shape the accepted paradigm of LSD1 as a driver of ligand-mediated PCa growth, and additionally place it as a central driver in the progression of both ligand-independent AR+ CRPC and AR null CRPC. These data strongly suggest that suppression of LSD1 in the clinical setting will not only inhibit AR-pathway dependent PCa, but will inhibit the growth and potentially prevent progression to fully-androgen independent CRPC, thereby establishing the rationale for LSD1 inhibition as an important, mechanism-based therapeutic target. To fully elucidate the activity of LSD1 in driving CRPC, this project will: 1. Determine the role of c-Myc in LSD1-mediated induction of ligand-independent proliferation pathways in castration sensitive and castration resistant PCa models; 2. Determine the anti-tumor efficacy of LSD1 suppression using the new LSD1 inhibitor SP-2509, alone or in combination with MDV3100, in ligand-independent AR+ and AR- preclinical CRPC models; and 3. Determine the biological effects, safety, and anti-tumor activity of the new LSD1 inhibitor SP-2509 in a phase I trial in men with metastatic CRPC. The need to target and translate key mechanisms such as the activity of LSD1, which is capable of simultaneously interdicting development of both AR-dependent and AR-independent mechanisms of progression and resistance, is an innovative approach of paramount importance and will yield novel data of immediate clinical translational relevance.
项目总结(见说明):
尽管引入了新的AR通路抑制剂,如阿比特龙和MDV 3100,但临床应答是短暂的,许多患者没有应答,这证明了配体和AR非依赖性机制在PCa进展中的重要性。该提案评估了染色质修饰酶LSD 1介导配体和AR非依赖性CRPC存活的新假设(扩展其先前确定的作为配体介导的AR活性驱动因子的功能)。具体来说,我们发现,i。LSD 1过表达在转移性CRPC中普遍存在,包括AR+和AR-肿瘤; ii.配体非依赖性LSD 1靶基因的主要类别涉及细胞周期和增殖的控制;和iii. LSD 1通过促进cMyc驱动的肿瘤生长以AR轴独立的方式起作用。我们的数据重新塑造了LSD 1作为配体介导的PCa生长驱动因素的公认范式,并将其作为配体非依赖性AR+ CRPC和AR null CRPC进展的中心驱动因素。这些数据强烈表明,在临床环境中抑制LSD 1不仅会抑制AR途径依赖性PCa,而且会抑制生长并可能阻止进展为完全雄激素非依赖性CRPC,从而确立了LSD 1抑制作为重要的基于机制的治疗靶点的基本原理。为了充分阐明LSD 1在驱动CRPC中的活性,本项目将:1。确定c-Myc在去势敏感和去势抵抗PCa模型中LSD 1介导的配体非依赖性增殖途径诱导中的作用; 2.在配体非依赖性AR+和AR-临床前CRPC模型中,确定使用新的LSD 1抑制剂SP-2509单独或与MDV 3100组合抑制LSD 1的抗肿瘤功效;和3.确定新的LSD 1抑制剂SP-2509在转移性CRPC男性中的I期试验中的生物学效应,安全性和抗肿瘤活性。需要靶向和翻译关键机制,如LSD 1的活性,它能够同时阻断AR依赖性和AR非依赖性进展和耐药机制的发展,这是一种至关重要的创新方法,将产生直接临床翻译相关的新数据。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joshi James Alumkal其他文献
Joshi James Alumkal的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joshi James Alumkal', 18)}}的其他基金
Targeting Prostate Cancer Lineage Plasticity with BET Bromodomain Inhibition
通过 BET Bromodomain 抑制来靶向前列腺癌谱系可塑性
- 批准号:
10220910 - 财政年份:2020
- 资助金额:
$ 21.9万 - 项目类别:
Targeting Prostate Cancer Lineage Plasticity with BET Bromodomain Inhibition
通过 BET Bromodomain 抑制来靶向前列腺癌谱系可塑性
- 批准号:
10026750 - 财政年份:2020
- 资助金额:
$ 21.9万 - 项目类别:
Targeting Prostate Cancer Lineage Plasticity with BET Bromodomain Inhibition
通过 BET Bromodomain 抑制来靶向前列腺癌谱系可塑性
- 批准号:
10405627 - 财政年份:2020
- 资助金额:
$ 21.9万 - 项目类别:
Targeting Prostate Cancer Lineage Plasticity with BET Bromodomain Inhibition
通过 BET Bromodomain 抑制来靶向前列腺癌谱系可塑性
- 批准号:
10631945 - 财政年份:2020
- 资助金额:
$ 21.9万 - 项目类别:
The Role of LSD1 in the Evolution of Castration Resistant Prostate Cancer
LSD1 在去势抵抗性前列腺癌演变中的作用
- 批准号:
8759224 - 财政年份:2014
- 资助金额:
$ 21.9万 - 项目类别:
The Role of LSD1 in the Evolution of Castration Resistant Prostate Cancer
LSD1 在去势抵抗性前列腺癌演变中的作用
- 批准号:
8879069 - 财政年份:2014
- 资助金额:
$ 21.9万 - 项目类别:
Targeting LSD1 in Neuroendocrine Prostate Cancer
靶向 LSD1 治疗神经内分泌前列腺癌
- 批准号:
10266055 - 财政年份:2014
- 资助金额:
$ 21.9万 - 项目类别:
The Role of LSD1 in the Evolution of Castration Resistant Prostate Cancer
LSD1 在去势抵抗性前列腺癌演变中的作用
- 批准号:
9090037 - 财政年份:2014
- 资助金额:
$ 21.9万 - 项目类别:
Targeting LSD1 in Neuroendocrine Prostate Cancer
靶向 LSD1 治疗神经内分泌前列腺癌
- 批准号:
10045656 - 财政年份:2014
- 资助金额:
$ 21.9万 - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
- 批准号:
10585802 - 财政年份:2023
- 资助金额:
$ 21.9万 - 项目类别:
Development of an apoptosis biosensor for monitoring of breast cancer
开发用于监测乳腺癌的细胞凋亡生物传感器
- 批准号:
10719415 - 财政年份:2023
- 资助金额:
$ 21.9万 - 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10605856 - 财政年份:2023
- 资助金额:
$ 21.9万 - 项目类别:
Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
- 批准号:
23K08773 - 财政年份:2023
- 资助金额:
$ 21.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanistic analysis of apoptosis induction by HDAC inhibitors in head and neck cancer
HDAC抑制剂诱导头颈癌凋亡的机制分析
- 批准号:
23K15866 - 财政年份:2023
- 资助金额:
$ 21.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10743485 - 财政年份:2023
- 资助金额:
$ 21.9万 - 项目类别:
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
研究细胞凋亡抗性和肿瘤环境对骶尾部畸胎瘤发生和维持的作用
- 批准号:
10749797 - 财政年份:2023
- 资助金额:
$ 21.9万 - 项目类别:
The effects of glucose on immune cell apoptosis and mitochondrial membrane potential and the analysis of its mechanism by which glucose might modulate the immune functions.
葡萄糖对免疫细胞凋亡和线粒体膜电位的影响及其调节免疫功能的机制分析。
- 批准号:
22K09076 - 财政年份:2022
- 资助金额:
$ 21.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION
P53 信号传导、细胞凋亡和肿瘤抑制中的 XAF1
- 批准号:
10583516 - 财政年份:2022
- 资助金额:
$ 21.9万 - 项目类别:
Role of Thioredoxin system in regulation of autophagy-apoptosis cross talk in neurons: Uncovering Novel Molecular Interactions.
硫氧还蛋白系统在神经元自噬-凋亡串扰调节中的作用:揭示新的分子相互作用。
- 批准号:
RGPIN-2019-05371 - 财政年份:2022
- 资助金额:
$ 21.9万 - 项目类别:
Discovery Grants Program - Individual